OPA1-associated disorders: Phenotypes and pathophysiology by P. Amati-Bonneau et al.
OPA1-associated disorders: Phenotypes and pathophysiology
Submitted by Emmanuel Lemoine on Wed, 12/11/2013 - 17:07
Titre OPA1-associated disorders: Phenotypes and pathophysiology
Type de
publication Article de revue
Auteur
Amati-Bonneau, Patrizia [1], Milea, Dan [2], Bonneau, Dominique [3], Chevrollier,
Arnaud [4], Ferré, Marc [5], Guillet, Virginie [6], Guegen, Naig [7], Loiseau,
Dominique [8], de Crescenzo, Marie-Anne Pou [9], Verny, Christophe [10],
Procaccio, Vincent [11], Lenaers, Guy [12], Reynier, Pascal [13]
Editeur Elsevier




Pagination 1855 - 1865
Volume 41
Titre de la
revue The International Journal of Biochemistry & Cell Biology
ISSN 1357-2725
Mots-clés dominant optic atrophy [14], Mitochondrial diseases [15], Optic nerve [16], Retinalganglion cells [17]
Résumé en
anglais
The OPA1 gene, encoding a dynamin-like mitochondrial GTPase, is involved in
autosomal dominant optic atrophy (ADOA, OMIM #165500). ADOA, also known as
Kjer's optic atrophy, affects retinal ganglion cells and the axons forming the optic
nerve, leading to progressive visual loss. OPA1 gene sequencing in patients with
hereditary optic neuropathies indicates that the clinical spectrum of ADOA is larger
than previously thought. Specific OPA1 mutations are responsible for several
distinct clinical presentations, such as ADOA with deafness (ADOAD), and severe
multi-systemic syndromes, the so-called “ADOA plus” disorders, which involve
neurological and neuromuscular symptoms similar to those due to mitochondrial
oxidative phosphorylation defects or mitochondrial DNA instability. The study of the
various clinical presentations of ADOA in conjunction with the investigation of OPA1
mutations in fibroblasts from patients with optic atrophy provides new insights into
the pathophysiological mechanisms of the disease while underscoring the multiple
physiological roles played by OPA1 in energetic metabolism, mitochondrial
structure and maintenance, and cell death. Finally, OPA1 represents an important
new paradigm for emerging neurodegenerative diseases affecting mitochondrial
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